Skip to main content
SpringerLink
Log in

Existing Insulin Therapies

  • Chapter
  • First Online:
Handbook of Insulin Therapies

Abstract

The insulin hormone is normally synthesized and stored as insulin–zinc hexameric aggregates in pancreatic beta cells. After release into the blood stream, the insulin complex dissociates into biologically active monomeric and dimeric forms which interact at insulin receptors to affect metabolic action. The aim of exogenously administered insulin therefore is to simulate physiological insulin action based primarily on modification of the human insulin molecule. Insulin has a tendency for self-association into dimers or hexamers. Rapid dissociation of hexamers to monomers accelerates the time to onset of action, whereas retarding agents such as protamine, zinc, amino acid substitutions and site-specific mutagenesis are employed to delay absorption and hence prolong action [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Brange J, Ribel U, Hansen JF, Dodson G, Hansen MT, Havelund S, et al. Monomeric insulins obtained by protein engineering and their medical implications. Nature. 1988;333:679–82.

    Article  CAS  PubMed  Google Scholar 

  2. Wendt D. Two tons of pig parts: making insulin in the 1920s. Smithsonian Institute Website. http://americanhistory.si.edu/blog/2013/11/two-tons-of-pig-parts-making-insulin-in-the-1920s.html. Accessed July 18, 2016.

  3. Goeddel DV, Kleid DG, Bolivar F, Heyneker HL, Yansura DG, Crea R, et al. Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc Natl Acad Sci U S A. 1979;76:106–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Thim L, Hansen MT, Norris K, Hoegh I, Boel E, Forstrom J, et al. Secretion and processing of insulin precursors in yeast. Proc Natl Acad Sci U S A. 1986;83:6766–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Starke AA, Heinemann L, Hohmann A, Berger M. The action profiles of human NPH insulin preparations. Diabet Med. 1989;6:239–44.

    Article  CAS  PubMed  Google Scholar 

  6. Richter B, Neises G. ‘Human’ insulin versus animal insulin in people with diabetes mellitus. Cochrane Database Syst Rev. 2005;(1):CD003816.

    Google Scholar 

  7. Cameron CG, Bennett HA. Cost-effectiveness of insulin analogs for diabetes mellitus. CMAJ. 2009;180:400–7.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Reutrakul S, Wroblewski K, Brown RL. Clinical use of U-500 regular insulin: review and meta-analysis. J Diabetes Sci Technol. 2012;6:412–20.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Crasto W, Jarvis J, Hackett E, Nayyar V, McNally PG, Davies MJ, et al. Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus. Postgrad Med. 2009;85:219–22.

    Article  CAS  Google Scholar 

  10. Fireman P, Fineberg SE, Galloway JA. Development of IgE antibodies to human (recombinant DNA), porcine, and bovine insulins in diabetic subjects. Diabetes Care. 1982;5 Suppl 2:119–25.

    Article  PubMed  Google Scholar 

  11. Airey CM, Williams DR, Martin PG, Bennett CM, Spoor PA. Hypoglycemia induced by exogenous insulin--‘human’ and animal insulin compared. Diabet Med. 2000;17:416–32.

    Article  CAS  PubMed  Google Scholar 

  12. Garber AJ, Davidson JA, Krosnick A, Beaser RS, Anderson Jr JH. Impact of transfer from animal-source insulins to biosynthetic human insulin (rDNA E coli) in patients with diabetes mellitus. Clin Ther. 1991;13:627–36.

    CAS  PubMed  Google Scholar 

  13. Leicester Diabetes Guidelines for Insulin Initiation 2013. University of Leicester Hospitals. www.leicestershirediabetes.org.uk/uploads//documents/Insulin_Guidelines_080114.pdf. Accessed July 18, 2016.

  14. Plank J, Siebenhofer A, Berghold A, Jeitler K, Horvath K, Mrak P, et al. Systematic review and meta-analysis of short-acting insulin analogs in patients with diabetes mellitus. Arch Intern Med. 2005;165:1337–44.

    Article  CAS  PubMed  Google Scholar 

  15. Plank J, Wutte A, Brunner G, Siebenhofer A, Semlitsch B, Sommer R, et al. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care. 2002;25:2053–7.

    Article  PubMed  Google Scholar 

  16. Rys P, Pankiewicz O, Łach K, Kwaskowski A, Skrzekowska-Baran I, Malecki MT. Efficacy and safety comparison of rapid-acting insulin aspart and regular human insulin in the treatment of type 1 and type 2 diabetes mellitus: a systematic review. Diabetes Metab. 2011;37:190–200.

    Article  CAS  PubMed  Google Scholar 

  17. Bolli GB, Luzio S, Marzotti S, Porcellati F, Sert-Langeron C, Charbonnel B, et al. Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. Diabetes Obes Metabol. 2011;13:251–7.

    Article  CAS  Google Scholar 

  18. Rostenstock J, Owens DR. Basal insulin in type 2 diabetes: Pt. 1 insulin glargine. Surrey: Aesculapium; 2004.

    Google Scholar 

  19. Davies M, Derezinski T, Pedersen CB, Clauson P. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technol Ther. 2008;10:273–7.

    Article  CAS  PubMed  Google Scholar 

  20. Havelund S, Plum A, Ribel U, Jonassen I, Vølund A, Markussen J, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res. 2004;21:1498–504.

    Article  CAS  PubMed  Google Scholar 

  21. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogs vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metabol. 2009;11:372–8.

    Article  CAS  Google Scholar 

  22. Sanches ACC, Correr CJ, Venson R, Gonçalves PR, Garcia MM, Piantavini MS, et al. Insulin analogs versus human insulin in type 1 diabetes: direct and indirect meta-analyses of efficacy and safety. Brazilian J Pharm Sci. 2013;49:501–9.

    Article  CAS  Google Scholar 

  23. Tricco AC, Ashoor HM, Antony J, Beyene J, Veroniki AA, Isaranuwatchai W, et al. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. BMJ. 2014;349:g54–9.

    Article  Google Scholar 

  24. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogs (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes. Diabetologia. 2004;47:622–9.

    Article  CAS  PubMed  Google Scholar 

  25. Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, et al. Long-acting insulin analogs versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;(2):CD005613.

    Google Scholar 

  26. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogs versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008;81:184–9.

    Article  CAS  PubMed  Google Scholar 

  27. Swinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;(7):CD006383.

    Google Scholar 

  28. Tran K, Banerjee S, Li H, Cimon K, Daneman D, Simpson SH, et al. Long-acting insulin analogs for diabetes mellitus: meta-analysis of clinical outcomes and assessment of cost-effectiveness. Technology report 92. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007. www.cadth.ca/media/pdf/341b_Long-acting-insulin_tr_e.pdf. Accessed July 18, 2016.

  29. Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, et al. Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379:1489–97.

    Article  CAS  PubMed  Google Scholar 

  30. Davies MJ, Gross JL, Ono Y, Sasaki T, Bantawal G, Gall MA, et al. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. Diabetes Obes Metab. 2014;16:922–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Zinman B, Phillis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial. Diabetes Care. 2012;35:2464–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, et al. Insulin degludec, an ultra-long-acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target noninferiority trial. Lancet. 2012;379:1498–507.

    Article  CAS  PubMed  Google Scholar 

  33. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29:2104–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care. 2013;36:2536–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Bode BW, Chaykin LB, Sussman AM, Warren ML, Niemeyer M, Rabøl R, et al. Efficacy and safety of insulin degludec 200 U/mL and insulin degludec 100 U/mL in patients with type 2 diabetes (Begin: Compare). Endocr Pract. 2014;20:785–91.

    Article  PubMed  Google Scholar 

  36. Valensi P. Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes. Diabetes Metab Syndr Obes. 2009;2:61–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Qayyum R, Bolen S, Maruthur N, Feldman L, Wilson LM, Marianopoulos SS, et al. Systematic review: comparative effectiveness and safety of premixed insulin analogs in type 2 diabetes. Ann Intern Med. 2008;149:549–59.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Hirsch IB, Bode B, Courreges JP, Dykiel P, Franek E, Hermansen K, et al. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial. Diabetes Care. 2012;35:2174–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Heise T, Tack CJ, Cuddihy R, Davidson J, Gouet D, Liebl A, et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care. 2011;34:669–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Niskanen L, Leiter LA, Franek E, Weng J, Damci T, Muñoz-Torres M, et al. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. Eur J Endocrinol. 2012;167:287–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. George Eliot Hospital NHS Trust, Nuneaton, United Kingdom

    Winston Crasto

  2. Leicester Diabetes Centre, Leicester General Hospital, Leicester, United Kingdom

    Janet Jarvis & Melanie J. Davies

Authors
  1. Winston Crasto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Janet Jarvis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Melanie J. Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Crasto, W., Jarvis, J., Davies, M.J. (2016). Existing Insulin Therapies. In: Handbook of Insulin Therapies. Adis, Cham. https://doi.org/10.1007/978-3-319-10939-8_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-10939-8_2

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-10938-1

  • Online ISBN: 978-3-319-10939-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation